Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s earnings beat estimates, its sales came in line. Earnings of $2.13 per ...

Merck (MRK) is seeing renewed attention from investors this week, thanks to a pivotal event in its oncology pipeline. The company, in collaboration with Daiichi Sankyo, just secured Breakthrough ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Merck (MRK) is set to present new clinical trial data at the European Society of Cardiology Congress 2025, emphasizing advancements in cardiovascular disease management. Over the last quarter, Merck's ...

Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include ...

Merck & Co. Inc. closed 28.45% below its 52-week high of $120.30, which the company achieved on September 6th.

Comparing Merck & Co's Short Interest Against Its Peers Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing.

Thursday’s market has seen significant movements among various stocks, with some experiencing sharp declines while others are rallying. In the mega-cap and large-cap categories, companies like ...

Now, it’s worth noting Stock Advisor’s total average return is 1,046% — a market-crushing outperformance compared to 183 % for the S&P 500.

Thursday, August 14, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s earnings beat estimates, its sales came in line.